2095432-71-4
2095432-71-4 structure
- Name: GSK269962 HCl
- Chemical Name: GSK269962A hydrochloride
- CAS Number: 2095432-71-4
- Molecular Formula: C29H31ClN8O5
- Molecular Weight: 607.06
- Catalog: Signaling Pathways Cell Cycle/DNA Damage ROCK
- Create Date: 2020-06-01 21:46:21
- Modify Date: 2024-01-22 20:45:53
-
GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities[1].
| Name | GSK269962A hydrochloride |
|---|
| Description | GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities[1]. |
|---|---|
| Related Catalog | |
| Target |
ROCK1:1.6 nM (IC50) ROCK2:4 nM (IC50) RSK1:132 nM (IC50) MSK1:49 nM (IC50) AKT1:955 nM (IC50) AKT2:1350 nM (IC50) AKT3:1510 nM (IC50) CDK2:3500 nM (IC50) GSK3α:1260 nM (IC50) |
| In Vitro | GSK269962A has an IC50 of 1.6 nM toward recombinant human ROCK1. GSK269962A exhibits more than 30-fold selectivity against a panel of serine/threonine kinases[1]. GSK269962A induces vasorelaxation in preconstricted rat aorta with an IC50 of 35 nM[1]. |
| In Vivo | GSK269962A is a potent antihypertensive agent. GSK269962A (0.3, 1, and 3 mg/kg; oral gavage) induces a dose-dependent reduction in blood pressure in spontaneously hypertensive rat (SHR). The reduction of blood pressure is acute and substantial[1]. Animal Model: Male Sprague-Dawley rats (350-400g)[1] Dosage: 0.3, 1, and 3 mg/kg Administration: Oral gavage; 12 hours Result: Induced a dose-dependent reduction in blood pressure. |
| References |
| Molecular Formula | C29H31ClN8O5 |
|---|---|
| Molecular Weight | 607.06 |